Jiangsu Nuohobito New Drug Research and Development

Jiangsu Nuohobito New Drug Research and Development is a clinical-stage biotechnology company headquartered in the China Medical City of Taizhou, Jiangsu. The company focuses on the discovery and development of first-in-class or best-in-class small molecule drugs for metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Utilizing a robust structure-based drug design (SBDD) platform, Nuohobito targets complex biological pathways such as G protein-coupled receptors (GPCRs) and nuclear receptors. Its lead asset, NHBT-001, is a selective GPR119 agonist that has entered clinical development for glycemic control. The company's pipeline also includes promising candidates targeting the thyroid hormone receptor beta (THR-beta) for liver-related metabolic disorders.